Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Atomwise is an industry leader in using AI and machine learning to discover new medicines, with more than $4.5 billion in deals and more than 685 discovery collaborations across 40 countries in every major therapeutic area including cancer, infectious disease and neurological disorders. Atomwise recently announced a discovery partnership with Hansoh Pharma, which marks the largest China-U.S. collaboration for AI in drug discovery — a deal that could amount to $1.5 billion. Atomwise has strategic and financial partnerships with Eli Lilly, Pfizer, Merck, Charles River Labs, Y Combinator, University of Michigan and Drugs for Neglected Disease initiative (DNDi), to name a few, and recently formed joint ventures to develop anticancer therapies with SEngine Precision Medicine, OncoStatyx and Atropos Therapeutics. Learn more at www.atomwise.com or on Twitter at @AtomwiseInc.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Atomwise’s lead product is its industry leading AI for drug discovery platform, AtomNet.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):